Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -76.66%-1.47M | -151.89%-1.84M | 57.09%-744.33K | -202.31%-4.36M | -142.07%-1.06M | -141.10%-829.8K | -89.63%-732.27K | -535.41%-1.73M | 14.77%-1.44M | 48.85%-437.61K |
| Net income from continuing operations | 74,823.01%7.62M | -182.82%-1.29M | 67.95%-1.06M | -570.97%-15.25M | -3,733.30%-13.5M | 101.75%10.18K | 332.72%1.56M | -396.28%-3.32M | -2.83%-2.27M | 77.03%-352.25K |
| Operating gains losses | ---- | ---- | ---- | -2,602.44%-1.4M | 7,941.04%139.51K | -27,496.95%-1.05M | -147,417.19%-2.89M | 4,765.00%2.4M | 85.86%-51.63K | 102.80%1.74K |
| Depreciation and amortization | --0 | --0 | --0 | -39.92%25.3K | --0 | -11.85%7.86K | -25.64%8.55K | -30.47%8.89K | -24.39%42.11K | -34.51%8.91K |
| Asset impairment expenditure | --500 | ---1K | ---78.75K | 4,173.82%12.06M | --12.06M | --0 | --0 | --0 | -281.74%-295.98K | ---- |
| Remuneration paid in stock | 54.47%97.6K | ---- | ---- | -6.35%242.5K | -15.17%56.27K | -3.69%63.19K | -3.66%61.84K | -2.57%61.2K | 281.01%258.94K | 290.35%66.33K |
| Remuneration paid in stock | 736.34%457.8K | --70.52K | --84.92K | --514.31K | --459.57K | --54.74K | --0 | --0 | --0 | --0 |
| Other non cashItems | -80.10%-54.51K | -946.48%-262.99K | -62.09%55.51K | -144.08%-58.15K | -766.29%-149.17K | -174.54%-30.27K | -174.50%-25.13K | 315.98%146.42K | -57.27%131.93K | -74.78%22.39K |
| Change In working capital | -469.23%-420.98K | -235.63%-664.42K | 126.46%257.73K | -165.73%-490.84K | -208.34%-120.54K | -9.70%114.02K | 183.56%489.88K | -389.51%-974.2K | 138.08%746.78K | -76.90%111.26K |
| -Change in receivables | -416.88%-87.97K | -200.53%-42.31K | 58.26%-26K | -82.85%4.99K | 63.78%-2.58K | 264.45%27.76K | 31.40%42.09K | -395.28%-62.28K | -64.45%29.12K | 81.81%-7.12K |
| -Change in prepaid assets | -532.66%-288.28K | 572.79%168.56K | -120.86%-22.25K | 87.88%11.25K | -113.12%-14.18K | 61.75%-45.57K | 74.20%-35.65K | -31.28%106.65K | -81.65%5.99K | 275.31%108.09K |
| -Change in payables and accrued expense | -133.93%-44.73K | -263.55%-790.67K | 130.04%305.98K | -171.25%-507.09K | -1,109.03%-103.78K | -49.74%131.82K | 73.34%483.45K | -735.78%-1.02M | 257.44%711.67K | -97.91%10.29K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -76.66%-1.47M | -151.75%-1.84M | 57.08%-744.33K | -202.31%-4.36M | -142.07%-1.06M | -141.10%-829.8K | -89.74%-732.67K | -535.27%-1.73M | 14.77%-1.44M | 48.85%-437.61K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 278.03%3.04M | -100.24%-1.12M | -290.18%-198.54K | -1,864.87%-2.3M | -92.33%12.12K | -10,863.61%-1.71M | -5,026.61%-558.03K | -4,589.86%-50.89K | 118.98%130.52K | 519.33%158.06K |
| Net PPE purchase and sale | -298.51%-1.97M | -100.24%-1.12M | -290.39%-198.54K | -935.52%-1.09M | -92.33%12.12K | -3,071.74%-493.75K | -5,026.61%-558.03K | -4,587.28%-50.86K | 118.98%130.52K | 519.33%158.06K |
| Net investment purchase and sale | ---- | ---- | ---- | ---28 | ---- | ---- | ---- | ---- | --0 | ---- |
| Net other investing changes | ---- | ---- | 78.57%-6 | ---1.21M | --29 | ---1.21M | --0 | ---28 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 278.03%3.04M | -100.24%-1.12M | -290.19%-198.55K | -1,864.87%-2.3M | -92.33%12.12K | -10,863.61%-1.71M | -5,026.61%-558.03K | -4,589.86%-50.89K | 118.98%130.52K | 519.33%158.06K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 363.65%6.97M | 14,321.19%2.74M | -57.38%1.67M | 400.37%6.37M | 72.43%975.73K | 551.22%1.5M | -104.04%-19.25K | 3.91M | -47.62%1.27M | 565.86K |
| Net issuance payments of debt | 99.87%-4.13K | -113.37%-532.27K | --0 | -48.64%473.69K | -220.83%-259.65K | -1,466.59%-3.16M | 735.41%3.98M | ---93.04K | -62.06%922.36K | --214.89K |
| Net common stock issuance | 45.96%5.84M | 223.22%4.93M | --0 | 1,567.93%5.85M | 428.03%1.85M | --4M | ---4M | --4M | --350.97K | --350.97K |
| Proceeds from stock option exercised by employees | --1.32M | --7.1K | --0 | --43.76K | --40.05K | --0 | --0 | --3.71K | --0 | --0 |
| Net other financing activities | ---- | ---- | --1.67M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 363.65%6.97M | 14,321.19%2.74M | -57.38%1.67M | 400.37%6.37M | 72.43%975.73K | 551.22%1.5M | -104.04%-19.25K | --3.91M | -47.62%1.27M | --565.86K |
| Net cash flow | ||||||||||
| Beginning cash position | -47.36%584.97K | -71.32%694.36K | -101.71%-5.04K | -11.16%294.85K | 817.06%78.27K | 708.82%1.11M | 4,086.70%2.42M | -11.16%294.85K | 18.97%331.9K | -99.30%8.54K |
| Current changes in cash | 927.07%8.54M | 82.88%-224.3K | -65.94%724.22K | -677.42%-288.06K | -124.97%-71.48K | -701.65%-1.03M | -1,746.47%-1.31M | 875.85%2.13M | -170.02%-37.05K | 132.05%286.31K |
| Effect of exchange rate changes | ---146.83K | --114.91K | ---24.82K | ---11.83K | ---11.83K | --0 | --0 | --0 | --0 | ---- |
| End cash Position | 11,375.14%8.98M | -47.36%584.97K | -71.32%694.36K | -101.71%-5.04K | -101.71%-5.04K | 817.06%78.27K | 708.82%1.11M | 4,086.70%2.42M | -11.16%294.85K | -11.16%294.85K |
| Free cash from | -159.38%-3.43M | -129.56%-2.96M | 42.77%-1.02M | -259.89%-5.45M | -130.38%-1.05M | -267.92%-1.32M | -225.09%-1.29M | -490.94%-1.79M | 40.77%-1.51M | 49.11%-454.55K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.